It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Integrated Diagnostics is creating large-scale, blood-based molecular diagnostics that leverage advances in proteomics and genomics to detect diseases such as lung cancer and Alzheimer’s at their earliest stages. …
…to rapidly turn medical breakthroughs into diagnostic assays by combining efforts to focus on protein and peptide biomarkers of disease.
…“… to realise the advantages of using a single technology platform from discovery and verification through to commercialisation.”
…The technology opens the possibility of screening for several hundred biomarkers in a single assay, in a very high-throughput and quantitative fashion…
WHERE DID THE BIOMARKERS (prions) COME FROM? WHAT CREATED THEM?
IS IT GENETIC? WHAT IS "GENETIC SUSCEPTIBILITY"?
More on Heredity here
Hereditary human prion disease Approximately 10-15% of people with prion disease have a genetic form. Genetic CJD is a single gene disorder due to mutations in the prion gene (PRNP) on chromosome 20. Presently more than 20 alterations in the DNA sequence in the gene have been reported. The characteristics of the disease correlate with the different mutation types. Several other changes in the PRNP gene (called polymorphisms) do not cause prion diseases, but may affect a person's risk of developing these diseases or alter the course of the disease.
The hypothesis that prions are able to replicate without a genome and to cause disease violated all conventional conceptions and during the 1980s was severely criticized. For more than 10 years, Stanley Prusiner fought an uneven battle against overwhelming opposition.
Future US Hematology and Flow Cytometry Market Outlook
Title: Future US Hematology and Flow Cytometry Market Outlook
Published: February, 2012
Price: US$ 9,500
New research report "Future US Hematology and Flow Cytometry Market Outlook" prepared by Venture Planning Group has been recently published by Market Publishers Ltd. The report reveals that commercialization of innovative products is likely to drive the future growth in the market, and the US will remain the biggest market for hematology.
London, UK (PRWEB) February 28, 2012
Increasing research and commercialization in the field of life sciences such as proteomics, genomics, pharmacogenomics, and stem cell research have resulted in a boosting of high-throughput technologies such as the flow cytometry market. However, several constraints, such as increased equipment cost, are hindering the market growth.
Also see: www.prweb.com...
What at first seemed an unusual mechanism restricted to a rather rare group of diseases has now become central to the study of all neurodegenerative conditions: the pathogenic proteins that characterise these diseases all seem to behave like prions. The implications for understanding how these diseases are transmitted through the nervous system and the possibility that environmental contamination may account for the sporadic forms of these diseases, as well as therapeutic possibilities, were among the topics discussed by the thirteen international experts, including two Nobel Prize winners, at the 27th annual colloquium on Alzheimer's disease, hosted by the Fondation IPSEN.
Originally posted by aboutface
reply to post by soficrow
GM1 was identified as a lipid. You're saying it's a protein. Is it a lipoprotein perhaps? As you can see, my knowledge is limited in biochemistry.